news roundup
The EndPandemic National Data Consortium has announced six life sciences and IT companies have committed to join the Consortium. The Consortium’s goal is to integrate data from all ongoing and future clinical studies to accelerate analysis on COVID-19 and SARS-CoV-2 research. The six companies are Andaman7, Caprion Biosciences, Clinerion, INDX.AI, Saama Technologies and Zaylan Associates (in partnership with Chrysalis Biomed Advisors).
Updated moves and miscellany come from Advarra, MMS Holdings, PRISYM ID, SGS, Syneos Health, WCG and more.
Advarra’s technologies are being implemented at Henry Ford Health System, Karmanos Cancer Insitute and Yale University.
There is still time to register and participate in the virtual The 2nd Annual Medical Hero Appreci-a-thon to express appreciation for all “Medical Heroes”—medical and healthcare professionals, researchers and study volunteers.
|
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
Events
| Search Upcoming Events |
| |
|
advertisement
Transforming Clinical Data Management
How technology and innovation are transforming data management, and enabling greater use of connected devices, in clinical trials
Tuesday, April 21, 2020 at 11am EDT | 8am PDT | 4pm BST |5pm CEST
Register now
|
|
|
|
|
|
|
|
|
|
|
Articles |
|
In this article, Applied Clinical Trials asked industry experts if there needs to be a change in clinical operations to clinical delivery, or maybe something else reimagined?
|
|
This article outlines the best practices and tactics for planning a comprehensive, program-wide data strategy, including what’s involved, who’s responsible, and when it should take place.
|
|
|
|
advertisement
Outsourcing to CROs: Expediting Clinical Operations or Oversight Nightmare?
How technology and innovation are transforming data management, and enabling greater use of connected devices, in clinical trials
Tuesday, April 28, 2020 1pm EDT | 12pm CDT | 10am PDT
Register now
|
|
Blog Posts
Signals of collaboration among private sector drug companies across much of the world to work together, even pooling their data in the search for prevention and cures, is an important event in the face of the pandemic.
It is clear that we have entered a new paradigm after COVID, writes Moe Alsumidaie. Companies that have piloted novel decentralized workflows are benefiting from new technologies that support study operations in this new environment. What else can sponsors do to succeed in the new normal?
|
|
|
|
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
|
